EUVIMEDEUVIMED entdecken
Crossref

Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients

Tarek Mahmoud iD, Jude Yagan iD, Amal Hasan iD, Osama A Gheith iD, Mohamed Mostafa, Suzann Rida, Nabil El-Serwi, Mohamad Shaker, Mahmoud Khalid

Clinical Transplantation · 2023-12 · 37 (12)

DOI: 10.1111/ctr.15144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 27.09.2023. Verfasst von Tarek Mahmoud und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Jaber Al Ahmed Armed Forces Hospital, Subhan, Kuwait. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Kidney Transplantation, Symporters. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cardiovascular and renal complications define the outcomes of diabetic kidney transplant recipients (KTRs). The new diabetes medications have changed the management of diabetes. However, transplant physicians are still reluctant to use sodium–glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) post kidney transplantation due to fear of drug related complications and lack of established guidelines. Patients and methods We collected 1‐year follow‐up data from records of 98 diabetic KTRs on SGLT2I, 41 on GLP‐ 1RA and 70 on standard‐of‐care medicines. Patients were more than 3 months post‐transplant with a minimum estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m 2 . Demographic data were similar except for a slightly lower HbA1c in the control group and higher albuminuria in SGLT2i group.

Results

HbA1c dropped significantly by .4% in both SGLT2i and GLP‐1RA compared to .05% in the control group. A significant decrease in BMI by .32 in SGLT2i and .34 in GLP‐1RA was observed compared to an increase by .015 in control group. A tendency for better eGFR in study groups was observed but was non‐significant except for the SGLT2i group with an eGFR above 90 ( p = .0135). The usual dip in eGFR was observed in the SGLT2i group at 1–3 months. Albuminuria was significantly reduced in both study groups. Adverse events were minimal with comparable safety in all groups.

Conclusion

The use of SGLT2i and GLP‐1RA appears to be effective and safe in diabetic KTRs with good outcomes. Randomized control trials are required to confirm these findings and establish guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Kidney TransplantationSymportersHumansHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinAlbuminuriaGlucoseSodium

Stichwörter der Autor:innen

diabetesglucagon-like peptide-1 receptor agonists (GLP-1 RA)kidney transplantationoutcomesodium-glucose co-transporter 2 inhibitors (SGLT2i)

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinSymportersGlucoseSodium

Autor:innen und Institutionen

  • Nephrology Department, Jaber Al Ahmed Armed Forces Hospital, Subhan, Kuwait.
  • Nephrology Department, Hamed Al-Essa Organ Transplant Center, Sabah Medical Region, Kuwait City, Kuwait.
  • Department of Translational Research, Dasman Diabetes Institute, Dasman, Kuwait.

ORCID-Profile: Tarek Mahmoud, Jude Yagan, Amal Hasan, Osama A Gheith

Zitieren

APA

Mahmoud, T., Yagan, J., Hasan, A., Gheith, O. A., Mostafa, M., Rida, S., El-Serwi, N., Shaker, M., & Khalid, M. (2023). Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients. Clinical Transplantation, 37(12). https://doi.org/10.1111/ctr.15144

Vancouver

Mahmoud T, Yagan J, Hasan A, Gheith OA, Mostafa M, Rida S, et al. Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients. Clinical Transplantation. 2023;37(12). doi:10.1111/ctr.15144

BibTeX
@article{Mahmoud2023,
  author = {Mahmoud, Tarek and Yagan, Jude and Hasan, Amal and Gheith, Osama A and Mostafa, Mohamed and Rida, Suzann and El-Serwi, Nabil and Shaker, Mohamad and Khalid, Mahmoud},
  title = {Sodium‐glucose co‐transporter 2 inhibitors & glucagon‐like peptide‐1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients},
  journal = {Clinical Transplantation},
  year = {2023},
  volume = {37},
  number = {12},
  doi = {10.1111/ctr.15144}
}
Kostenlos starten →